Cancel

Hematologic Malignancies Demystified - Atlanta A Critical Appraisal of Data from 2018

Explore the options in hematology and hematologic malignancies with this live meeting. Stay informed on new data with established agents and gain insight into the use of novel agents in your practice. Expert faculty will focus on updates from recent congresses and the latest clinically relevant data.
This activity is provided by The University of Texas MD Anderson Cancer Center and prIME Oncology.

Hematologic Malignancies Demystified - Houston A Critical Appraisal of Data from 2018

Explore the options in hematology and hematologic malignancies with this live meeting. Stay informed on new data with established agents and gain insight into the use of novel agents in your practice. Expert faculty will focus on updates from recent congresses and the latest clinically relevant data.
This activity is provided by The University of Texas MD Anderson Cancer Center and prIME Oncology.

Melanoma: Updates from Brisbane, Australia The latest data in melanoma reported at the joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma

Roxana S. Dronca, MD, and Lisa A. Kottschade, APRN, MSN, CNP, offer their expert insights into recent data on advanced melanoma presented at a joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research. Listen to what these experts have to say about combination therapy in the adjuvant setting for metastatic melanoma, real-world utilization of checkpoint inhibitor therapy, sequencing options for BRAF +/- MEK Inhibition following immu...
Annenberg Center for Health Sciences at Eisenhower

Current Challenges and New Opportunities in Follicular Lymphoma

STATEMENT OF NEED Of the estimated 74,680 new cases of non-Hodgkin lymphoma each year in the United States, approximately 35% are follicular lymphoma (FL), an indolent, difficult-to-treat B-cell malignancy. Most patients are diagnosed at an average age of 65 years. Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with availab...
Postgraduate Institute for Medicine and i3 Health

Applying Advances with Checkpoint Inhibitors in Thoracic Oncology

Lung cancer is a leading cause of cancer-related deaths worldwide. It is estimated that 222,500 new cases of lung cancer will occur in the United States in 2018, resulting in 155,870 deaths. Mesothelioma, a cancer that can develop in the lining of the lungs, is commonly caused by exposure to asbestos and is associated with a poor prognosis. Advances in lung cancer treatment, including the introduction of immune checkpoint inhibitors, are increasing the number of patients who receive treatment ...
Slack Inc.

Treatment Strategies in Chronic Leukemias and Introduction to CAR-T Therapy

Chronic lymphocytic (CLL) and chronic myelogenous (CML) leukemia are commonly diagnosed and treated by community oncologists. Whereas, in the past, these hematologic malignancies were considered incurable, new therapies have challenged that notion. Tyrosine kinase inhibitors (TKIs) annihilated the concept of CML as a poorly controlled disease, and most patients are now expected to live a normal life, with good quality of life. New testing procedures have suggested that some patients may be ...
Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology

Payment Models and Practice Changes: Meeting Requirements of OCM & MACRA

Recent legislation and policy has fast-tracked the shift of healthcare payment from volume- to value-based reimbursement under the Medicare Access and CHIP Reauthorization Act (MACRA) for oncology care. Today, oncologists have the option to be reimbursed for Medicare patients under the CMS Oncology Care Model (OCM), an alternative payment model spanning a 6-month chemotherapy episode-of-care. This activity will provide insight into the program’s structure and challenges. It will also review ...
Potomac Center for Medical Education, Postgraduate Institute for Medicine and Rockpointe Oncology

Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Improving outcomes for patients with multiple myeloma requires building on the foundation of current therapies with new agents and combinations, recognizing the nature of each individual patient’s disease, and providing a personalized approach to treatment. This activity uses evidence-based presentations and case study vignettes to present the latest information on selecting the most appropriate therapy based on patient profile, clinical evidence, and assessment of risk-versus-benefit. Le...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Evidence-based Updates in Non-Hodgkin’s Lymphoma

Significant advances in treatment with novel agents for B-cell non-Hodgkin’s lymphoma (NHL) have improved patient outcomes and survival. However, many patients are at high-risk of relapse, meriting a precision approach to reduce the rate of recurrence and improve outcomes. The identification of molecular subtypes, the persistence of clinical challenges, and the anticipated emergence of clinical data necessitate a collaborative treatment approach to ensure individualized care for patients wit...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Checkpoint Inhibitors in Gastrointestinal Tumors: The Latest Evidence on Safety, Efficacy, and Biomarkers

The genomes of cancers deficient in mismatch repair (MMR) contain extremely high numbers of somatic mutations. Analysis of recent clinical studies have demonstrated that colorectal cancers with mismatch repair deficiency (dMMR) and other advanced dMMR cancers are sensitive to immune checkpoint blockade with PD-1 antibodies, and that mutational burden correlates with treatment response. These findings have led to the recent approval of two immune checkpoint inhibitors for the treatment of micro...
Slack Inc.

Navigating New Options to Improve Outcomes in Multiple Myeloma

As new combinations and classes of agents emerge for the treatment of multiple myeloma (MM), community-based treatment teams require clarity on the optimal integration of recently approved and emerging agents into the relapsed/refractory landscape for MM. While high-dose chemotherapy is not appropriate for all patients, multiple options have emerged that demonstrate a clinical benefit and require proper integration into the treatment paradigm. In addition, clinicians must meet requirements for...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Targeted Therapy for Skin Malignancies: Basal Cell Carcinoma, Melanoma, and Merkel Cell

Patients may not always be offered the most appropriate single and combination targeted therapies that have been proven effective in clinical trials. Currently available clinical data have practice-changing implications for medical oncologists, dermatologists, and related specialists treating skin malignancies. To stay up to date with the latest data, evidence will be presented related to the role of BRAF inhibition, hedgehog signaling, and immunotherapy in the pathogenesis and treatment of ba...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Advancing Standards in the Management of Hemophilia A: Contemporary Strategies and Innovations

The US health care ecosystem has undergone a profound transformation in recent years, with far-reaching implications for patients with hemophilia A. Clinical management of patients with hemophilia has become increasingly complex due to the introduction of new treatment strategies, the presence of comorbidities related to hemophilia, and the increased emphasis on outcomes such as quality of life, to balance both the medical and lifestyle consequences of the disease. Patients with severe hemophi...
CMEology

Precision Medicine and Impact of Therapeutic Drug Levels

Much has been written recently about the need for genetic testing and biomarkers to identify specific targets within cancers, recognizing that there are many subclones and individual differences within the malignancies that arise in patients, even in those with morphologically similar cancers. Another important aspect of cancer treatment is the need to optimize the dose and schedule of administered therapies. Pharmacogenomics has demonstrated that the bioavailability and half-lives of anti-ca...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Targeting EGFR, T790M, ALK, and ROS1 in NSCLC

Oncology treatment teams are tasked with navigating through a steady increase in the number and complexity of molecular biomarkers that guide treatment decisions. FDA-approved companion tests have expanded testing options and provide uniformity of reporting, yet challenges in the clinical setting and the potential to negatively impact patient outcomes persist. As part of the continuum of care in oncology, there is an increasing demand for genomic testing to guide the course of treatment. Misi...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Ace the Case: A 35-Year-Old Man Presents to a Dermatologist with a Brown Pigmented Lesion That Has Been Changing Over the Past 3 Months

This educational activity will utilize a case study to discuss the diagnosis and management of a 35-year-old man who has a brown pigmented lesion that has been changing over the past 3 months.
Slack Inc.

Medical Oncology and Hematology 2019: Multidisciplinary Approaches that Improve Coordination of Care

www.mdanderson.org/conferences
MD Anderson

Clinical and Multidisciplinary Hematology and Oncology 2019 : The 16th Annual Review

This course will include a comprehensive update and management strategies of issues in hematologic and oncologic malignancies presenting new disease classification, treatment, and challenging cases. Course topics will focus on hematologic diseases, solid tumors and overlap topics of supportive, ancillary and diagnostic care. The course offers challenging and interactive sessions on pertinent issues involved with the care of patients.
Mayo Clinic

Rheumatic Immune-related Adverse Events: Multidisciplinary Perspectives on Recognition and Management

The introduction of immune checkpoint inhibitors has had a great impact on the field of oncology. However, these new therapies are associated with a spectrum of autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatologists are likely to encounter a wide variety of irAEs as the use of immune checkpoint inhibitors expands in the treatment of several cancers. Thus, it is critical for rheumatologists to be aware of these complications to accurately ...
Slack Inc.

Achieving Precision Care in Gastrointestinal Cancers

Treatment selection is largely dependent on the goals of therapy; however, sequencing of standard therapies with newly approved therapies as patients’ progress is a key factor in improving quality of care. The recent approval of new agents and advances in biomarker detection have supported the individualization of treatment and subsequent improvements in survival for patients with gastrointestinal cancers. As new agents are expected to enter the treatment paradigm in 2017, clinicians will r...
The Potomac Center for Medical Education, Postgraduate Institute for Medicine, and Rockpointe Oncology.

Optimizing Patient Outcomes in Castration-Resistant Prostate Cancer: Moving Urologists From Knowledge to Action

Evan Ya-Wen Yu, MD, provides his insights into the evolving management of patients with castration-resistant prostate cancer (CRPC) and the implications of the genomic landscape on CRPC. Since clinical trial evidence does not clearly inform sequencing strategies, Dr. Yu weaves his insight into this conundrum using 3 cases, with suggestions to help the urologist individualize treatment. CONTENT AREAS • National Comprehensive Cancer Network guidelines on prostate cancer • Clinical tria...
Annenberg Center for Health Sciences at Eisenhower

Advances in the Multidisciplinary Management of Hepatocellular Carcinoma (HCC): Strategies for Incorporating Emerging Immunotherapy Treatment Options

Expert faculty, Richard Finn, MD, discusses treatment options and strategies in a case-based approach for two patients who have failed conventional therapies and may be candidates for immunotherapy. The activity features an online virtual patient platform that affords clinicians an opportunity to absorb relevant clinical and evidence-based information. The purpose of the activity is to inform clinicians on integrating immunotherapy into treatment options of advanced hepatocellular carcinoma pa...
ACHL

3rd Annual Therapeutic Advances for Advanced Practice Providers and Nurses: Hematology/Oncology Patient Care and Challenges 2019

Mayo Clinic's 3rd Annual Therapeutic Advances for Advanced Practice Providers and Nurses: Hematology/Oncology Patient Care and Challenges 2019 will be held in Jacksonville, Florida. This continuing medical education (CME) conference will focus on the needs of advanced practice providers, nurse practitioners, ARNPs (APRN), and nurses regarding the care of patients with hematologic and oncologic malignancies. The course will feature lectures, case presentations, panels discussions, interactive g...
Mayo Clinic

Hematology/Oncology & Cardiorespiratory/Renal Physiology and Medicine Eastern Caribbean Cruise

TBA
Continuing Education, Inc

Internal Medicine Comprehensive Review and Update 2019

This CME program from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices for: • Cardiovascular Medicine • Pulmonary Medicine • Critical Care • Hematology and Oncology • Mind-Body Medicine • Infectious Diseases • Gastroenterology • Endocrinology • Rheumatology • Nephrology • Travel Medicine • Allergy and Immuno...
Harvard Medical School

The Brigham Board Review in Hematology

Topics covered by The Brigham Board Review in Hematology include:  Hematopoietic Stem Cell Transplantation, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndromes, Hodgkin's Lymphoma, Bone Marrow Failure, Hemophagocytic Syndromes, Sickle Cell Disease, Thalassemia and many others. After completing The Brigham Board Review in Hematology, you will be able to: • Apply current/recommended Hematology guidelines in clinical practice • Perform differential diagnosis of comple...
CMEInfo

The Brigham Board Review in Hematology and Oncology

Get ready for the ABIM exam in Hematology-Oncology by studying this Brigham Board Review in Hematology and Oncology. Topics covered by the Brigham Board Review in Hematology and Oncology include: Molecular Genetics of Cancer, Cancer Drug Development, Hematopoietic Stem Cell Transplantation, Acute Leukemias, Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, B Cell Malignancies, Mesothelioma, Thyroid Cancer and dozens of others. After completing the Brigham Board Review in Hemat...
CMEInfo

Crucial Conversations in Oncology Nursing: Management Considerations for the AML Patient

The landscape of AML treatment is evolving and newer targeted agents may improve outcomes for selected subgroups of patients. Oncology nursing professionals provide disease and treatment information, manage adverse effects, and offer emotional support. Knowledge of the key management issues for patients with AML is critical in fulfilling this role. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and po...
American Academy of CME

12th International Congress on Myeloproliferative Neoplasms

Since its inception 18 years ago, the International Congress on Myeloproliferative Neoplasms has provided a forum for the interaction of practicing hematologists, oncologists, translational scientists, and other healthcare professionals with experts from both the US and Europe in the myeloproliferative neoplasms, including chronic myeloid leukemia, the hyper-eosinophilic syndromes and mastocytosis. This year’s CME-accredited program will feature the latest information on the pathophysiology ...
Melton Medical Education, LLC

TKI Therapy in CML: Emerging Treatments, Ensuring Safety

This Virtual Practice summarizes advances in tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) in the context of disease- and patient-specific characteristics; reviews the most effective methods for monitoring early response and long-term therapeutic outcomes; assesses the milestones and mutational analyses to identify when a change in TKI therapy is needed; compares toxicity profiles of the currently available TKI agents; and examines how toxicity could interact with...
Albert Einstein College of Medicine and RedMedEd

Board Vitals Hematology and Oncology Board Review Question Bank

The Hematology and Oncology Board Review Question Bank features over 800 Hematology and Oncology questions. The Hematology Oncology exam study guide features: • Over 800 review questions and answers • The leading digital question bank for Oncology Board Prep • Percent correct provided on most questions to compare against the national average • Timed mode available to simulate exam conditions • Access from any computer or smartphone! • Also available: CME Redemption
Board Vitals

The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

The clinical multiple myeloma arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope to patients, but it presents new challenges for the clinicians charged with their care. Some patients enjoy many years in clinical remission, whereas for others survival is no more than 2 or 3 years. This reflects the heterogeneity of myeloma and underscores the inappropriateness of a one-size-fits-all ma...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

The University of Chicago Digestive Diseases Review: University of Chicago Medicine & Biological Sciences Specialty Review (SA-CME)

Studying the University of Chicago Digestive Diseases Review will help you to better: • Keep up with the latest advancements regarding the biology and treatment of patients with digestive diseases • Apply new knowledge in GI, hematology, and nutrition with this review in gastroenterology • Integrate current guidelines into daily practice when preventing and managing digestive diseases
CMEInfo

Board Vitals Family Medicine MOC Re-Certification Question Bank and Review

Board Vitals Family Medicine MOC Re-Certification Question Bank and Review contains over 1500 ABFM and AOBFP Family Medicine MOC targeted review questions. The Board Vitals FM qbank offers questions that are directly relevant to the exam: multiple choice questions (mostly focused around patient scenarios) with a single best answer. Board Vitals Family Medicine MOC Re-Certification Question Bank Features: • Take the exam in review mode or timed mode to simulate real FM exam conditions • ...
Board Vitals

Board Vitals USMLE Step 2 Board Review Questions and Practice Tests

Board Vitals USMLE Step 2 Board Review Questions and Practice Tests • Over 1000 USMLE Step 2 Board Review Questions • 100% Pass Guarantee! • Higher Pass Rate Than The National Average • Individualized Learning Based on Performance
Board Vitals

Board Vitals USMLE Step 3 Board Review Questions

Board Vitals USMLE Step 3 Board Review Questions: • 1200 USMLE Step 3 board review questions • Individualized learning • Ability to flag questions for further review • Question are structured by category • Timed and review modes available • Detailed explanations associated with each question
Board Vitals

Board Vitals Internal Medicine Board Review Question Bank and Study Program

The Board Vitals Internal Medicine Board Review Question Bank and Study Program covers topics from Allergy and Immunology to Pulmonary topics - all of the subjects covered on the Internal Medicine Board Exam.  The bank offers over 1200 questions targeted to the ABIM and ABOIM exams.  The Internal Medicine review is highly interactive, offers high yield questions, and offers related images in a manner similar to the board exams.
Board Vitals

Osler Pathology Online Review

After completing the Osler Pathology Online Review, you will be able to: • Use the evidence-based information and practice tools presented to better formulate differ- ential diagnoses for most clinical scenarios • Effectively apply current practice guidelines published by CAP, ASCP and other major medical and governmental agencies • Recognize common patterns of test results and recommend additional tests, as needed, to characterize the etiology and prognosis of individual patient cond...
Osler Institute

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.